Details

Autor(en) / Beteiligte

• Zhang, Xiao-Jing
• Ji, Yan-Xiao
• Cheng, Xu
• Cheng, Yanjie
• Yang, Hailong
• Wang, Junyong
• Zhao, Ling-Ping
• Huang, Yong-Ping
• Sun, Dating
• Xiang, Hui
• Shen, Li-Jun
• Li, Peng-Long
• Ma, Jun-Peng
• Tian, Rui-Feng
• Yang, Juan
• Yao, Xinxin
• Xu, Haibo
• Liao, Rufang
• Xiao, Li
• Zhang, Peng
• Zhang, Xin
• Zhao, Guang-Nian
• Wang, Xi
• Hu, Man-Li
• Tian, Song
• Wan, Juan
• Cai, Jingjing
• Ma, Xinliang
• Xu, Qingbo
• Wang, Yibin
• Touyz, Rhian M
• Liu, Peter P
• Loomba, Rohit
• She, Zhi-Gang
• Li, Hongliang

Titel

A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaques

Ist Teil von

• Science translational medicine, 2021-12, Vol.13 (624), p.eabg8116

Ort / Verlag

United States

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• Nonalcoholic steatohepatitis (NASH) is a progressive liver disease and has become a leading indication for liver transplantation in the United States. The development of effective therapies for NASH is a major unmet need. Here, we identified a small molecule, IMA-1, that can treat NASH by interrupting the arachidonate 12-lipoxygenase (ALOX12)–acetyl-CoA carboxylase 1 (ACC1) interaction. IMA-1 markedly blocked diet-induced NASH progression in both male mice and macaque therapeutic models. The anti-NASH efficacy of IMA-1 was comparable to ACC inhibitor in both species. Protein docking simulations and following functional experiments suggested that the anti-NASH effects of IMA-1 were largely dependent on its direct binding to a pocket in ALOX12 proximal to its ACC1-interacting surface instead of inhibiting ALOX12 lipoxygenase activity. IMA-1 treatment did not elicit hyperlipidemia, a known side effect of direct inhibition of ACC enzymatic activity, in both mice and macaques. These findings provide proof of concept across multiple species for the use of small molecule–based therapies for NASH.